Background/Aims: Exosomal circulating long non-coding RNAs (lncRNAs) in blood are emerging as clinically useful and non-invasive biomarkers for tumor diagnosis. However, normal cells can also secrete exosomes, so it is a prerequisite to obtain tumor-derived exosomes for better understanding of their diagnostic impacts in cancer. In this study, a dual-antibodyfunctionalized immunoaffinity system was established to isolate exosomes and investigate their lncRNAs expression pattern and clinical significance in prostate cancer (PCa). Methods: A commercially available kit was used to isolate total exosomes, which were then purified by a dual-antibody-functionalized immunoaffinity system. RT-qPCR was performed to detect the expression of exosomal lncRNAs. Receiver operating characteristic (ROC) curves were plotted to assess the diagnostic value. Results: Expression levels of two lncRNAs in tumor-derived exosomes were significantly higher than those in total exosomes. The levels of SAP30L-AS1 were upregulated in benign prostatic hyperplasia (BPH), and SChLAP1 levels were significantly higher in PCa than in BPH and healthy individuals. The area under the ROC curve indicated that SAP30L-AS1 and SChLAP1 had adequate diagnostic value to distinguish PCa from controls. Two lncRNAs separately combined with prostate specific antigen (PSA) possessed a moderate ability for discrimination. SAP30L-AS1 expression level was related to PSA values and tumor invasion. SChLAP1 expression was significantly higher in patients with higher Gleason scores, and was also effective in differentiating between BPH and PCa when the concentration of PSA
Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer
Yu-Hui Wang In this study, a novel dual-antibody immunoaffinity-based method was developed to isolate tumor-derived exosomes from patients' plasma and to investigate whether lncRNAs in exosomes from plasma can serve as diagnostic biomarkers in PCa. Our approach was found to specifically enrich tumor-derived exosomes from total exosome samples isolated from plasma. Subsequently, tumor specific lncRNAs, SAP30L-AS1 and SChLAP1, inside tumor-derived exosomes were quantified by real-time RT-PCR and retrospectively analyzed, together with patients' clinical parameters. The area under the ROC curve indicated that SAP30L-AS1 and SChLAP1 had adequate diagnostic value to distinguish PCa from controls. Two lncRNAs separately combined with PSA possessed a moderate ability for discrimination. SAP30L-AS1 expression level was related to PSA values and tumor invasion. SChLAP1 expression was significantly higher in patients with higher Gleason scores and it was also effective in differentiating between BPH and PCa when the concentration of PSA was in the gray zone. Taken together, our dual-antibody immune-affinity approach could be an effective platform for enriching tumor-specific exosomes for diagnosis and for guidance as to potential therapies for treating different cancers.
Materials and Methods

Cell culture
Human PCa cell line LNCaP cells were purchased from the China Center for Type Culture Collection (CCTCC; Wuhan, China). Cells were grown in RPMI1640 (HyClone Laboratories, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientifc, Inc., Waltham, MA, USA) and 1% penicillin-streptomycin (Beyotime, Shanghai, China) in a humidified atmosphere at 37℃ with 5% CO 2 . Cells were harvested for analysis at 80-90% confluence.
Plasma sample collection
Peripheral blood samples were obtained from Zhongnan Hospital of Wuhan University, China, from September of 2016 to May of 2017. Control blood samples were obtained from 30 healthy volunteers with concentration of PSA less than 4 ng/ml. Forty-six patients with BPH and 34 patients with PCa were enrolled in the study. The clinical parameters of all participants were available. All patients were Chinese and the characteristics of the studied subjects are summarized (for all online suppl. material, see www. karger.com/doi/10.1159/000488620) in Table S1 . Biopsies from all patients were diagnosed and graded by board certified pathologists in Zhongnan Hospital. Peripheral blood samples were collected in EDTA tubes, then centrifuged at 2000 × g for 5 minutes at 4℃ to remove cells. The supernatants were transferred to microcentrifuge tubes and the remaining cells and debris were removed by centrifugation at 2, 000 × g for 20 minutes at 4℃. Subsequently, the supernatants were transferred to a new tube without disturbing the pellet and centrifuged at 10, 000 × g for 20 minutes at 4℃ to remove more debris. The supernatants were kept as plasma samples and stored at -80℃ until use.
Total exosomes isolation
Total exosomes were isolated from either conditioned cell culture medium or plasma samples. For exosome isolation from culture medium, cells were grown to 80% confluence in 75 cm² flasks (Corning Incorporated, Corning, NY, USA), and then the culture medium was removed. The cells were washed with phosphate buffered saline (PBS) three times and cultured in FBS-free RPMI1640 medium for 48 hours. Subsequently, total cell culture medium was harvested from three 75 cm² flasks and centrifuged at 2000 × g for 30 minutes to remove suspended cells and debris. Total Exosome Isolation Reagent (from cell culture media) (Invitrogen, Carlsbad, CA, USA) was used to isolate total exosomes following the manufacturer's instructions.
For exosomes isolation from plasma, approximately 400 μl of plasma was thawed in a water bath at 37℃. Exosomes were isolated using Total Exosome Isolation Reagent (from plasma) (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Transmission electron microscopic analysis Transmission electron microscopy (TEM) was performed at Wuhan Institute of Virology, China. Negative staining was applied for TEM measurement. Fresh exosomes were resuspended in PBS and 10 μl of exosome sample was loaded on a 300-mesh copper grid (carbon coated), followed by room temperature drying for 5 minutes. In addition, 5 μl of phosphotungstic acid was loaded onto the grid. Excess liquid was wicked off using filter paper after 5 minutes of incubation and the grid was air dried for 10 minutes. Samples were observed using a Tecnai G20 TWIN Transmission Electron Microscope (FEI, USA), imaged, and analyzed at 200 kV.
Western blot analysis
LNCaP cells were harvested and suspended in radioimmunoprecipitation assay (RIPA) buffer containing the protease inhibitor cocktail. BCA Protein Assay Kit (Beyotime, China) was used to quantify protein concentrations. Then cell lysates and exosomes were loaded onto the SDS-PAGE gel. The electrophoresed proteins were transferred to PVDF membranes (Millipore, USA). Membranes were blocked in 5% nonfat milk, followed by overnight incubation with diluted CD63 and TSG101 antibodies (1:1, 000; Proteintech Group, Chicago, IL, USA). Membranes were washed and probed with a horseradish peroxidase-conjugated secondary antibody (1:5, 000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Dynamic light scattering analysis
Dynamic light scattering (DLS) analysis was applied to measure the size of exosomes using the Zetasizer Nano ZS90 instrument (Malvern, UK). Exosome samples diluted in PBS were analyzed in an equilibration time of 70 seconds at a constant temperature of 25℃. Samples were calibrated by CPC100 standard particles diluted 1, 000-fold under identical settings.
Isolation of tumor-derived exosomes by dual-antibody-functionalized immunoaffinity system.
Dynabeads™ M-280 Streptavidin magnetic beads (Life technologies AS, Oslo, Norway) were conjugated with biotin anti-human EpCAM antibody (R&D Systems, Minneapolis, MN, USA) and biotin anti-human PSMA antibody (BioLegend, San Diego, CA, USA), according to the protocols supplied by manufacturers. Total exosomes (from 400 μl plasma or three 75 cm² flasks) were incubated with conjugated-magnetic beads (20 μl) at 4℃ for 16 hours. The beads were washed with PBS three times then suspended either in RIPA buffer containing the protease inhibitor cocktail or in RNAiso Blood (TaKaRa, Tokyo, Japan), and were stored at -20℃ until use.
Quantitative real-time PCR
Total RNA from total exosomes and tumor-derived exosomes was extracted using RNAiso Blood (TaKaRa, Tokyo, Japan) following the manufacturer's instructions, and then dissolved in 10 μl diethylpyrocarbonate-treated water. The quality of RNA was assessed by a Thermo Scientific™ Nanodrop 2000 platform (Thermo Fisher Scientific, Waltham, MA, USA). Finally, the extracted RNA was used to synthesize cDNA using ReverTra Ace-α First-strand cDNA Synthesis Kit (Toyobo, Osaka, Japan). The levels of lncRNAs were assessed on the StepOnePlus™ Real-time PCR System (Applied Biosystems, Foster City, CA, USA) using SYBR® Green Realtime PCR Master Mix (Toyobo, Osaka, Japan) according to the manufacturer's instructions. The internal control was GAPDH [37] , and its primer sequences were as follows: forward primer, 5′-AGACTTGTCCAACCACTAGAACT-3′; reverse primer, 5′-AGGGCTGAGGGCTGATTC-3′. The sequences of primers for SChLAP1 were as follows: forward primer, 5′-TGGACACAATTTCAAGTCCTCA-3′; reverse primer, 5′-CATGGTGAAAGTGCCTTATACA-3′. The sequences of primers for SAP30L-AS1 were as follows: forward primer, 5′-TGAATGGGCTCACCTGTTCC-3′; reverse primer, 5′-AGGTCCGGAAGGGAGACTTT-3′. The reactions started at 95℃ for 1 min, followed by 40 cycles of 95℃ for 15 seconds, 60℃ for 20 seconds and 72℃ for 45 seconds. The levels of lncRNAs were determined by the 2 -ΔΔCt method. All experiments were carried out twice with negative control.
Statistical analysis
Data were analyzed by GraphPad Prism V.5.00 software (GraphPad Software, San Diego CA, USA) and SPSS 15.0 (SPSS, Inc., Chicago, IL, USA). One-way analysis of variance (ANOVA) was used to investigate the differences between groups. ROC curve was applied to evaluate the diagnostic value. Differences between 
Results
Isolation and characterization of exosomes from cell culture supernatant using dualantibody-functionalized immunoaffinity system Exosomes were first isolated from conditioned cell culture medium using a commercial kit. TEM pictures showed that the vesicle size of isolated exosomes ranged from 30 to 120 nm in diameter (Fig. 1A) . The presence of exosomal marker protein CD63 was then analyzed by western blotting (Fig. 1B) . Exosomal marker protein CD63 was enriched in exosome fractions as compared to cell lysates (Fig.  1B) . To further enrich prostate tumor-derived exosomes, an immunoaffinity system was developed using magnetic beads conjugated with both anti-EpCAM and anti-PSMA antibodies based on our previous related researches (Fig. 1C) . To validate our isolation procedure, CD63 was probed on the samples from different fractions of the isolation process by western blotting. As shown in Fig. 1D , the expression of CD63 for a certain number of total exosomes was pictured in the lane 1. Then, the magnetic beads conjugated with anti-EpCAM and anti-PSMA antibody could effectively capture exosomes in equal amounts of total exosomes (lane 2 of Fig. 1D ), whereas there were significantly fewer exosomes in magnetic beads unbound fraction (lane 3 of Fig. 1D ). To test whether magnetic beads could nonspecifically bind to exosomes, unconjugated magnetic beads were incubated with exosomes, and it was found that magnetic beads alone had minimal capacity to bind to exosomes (lane 4 of Fig. 1D ), while most exosomes were present in the unbound fraction (lane 5 of Fig. 1D ). Thus, the exosomes captured by conjugated magnetic beads were most likely to bind to dual-antibody as opposed to magnetic beads. Based on recent literature and previous work in our laboratory (research in the molecular profiling of pooled circulating tumor cells from PCa patients using dual-antibody-functionalized microfluidic device), it was decided to detect two lncRNAs in tumor-derived exosomes and validate them in the TCGA database (see online suppl. material, Fig. S1 ). The two lncRNAs were SChLAP1 and SAP30L-AS1, which were closely related to PCa. Expression of the two lncRNAs in tumor-derived exosomes was significantly higher than that in total exosomes, which indicated that these lncRNAs were enriched in tumorderived exosomes (Fig. 1E ) and might be potential biomarkers for PCa. To further test our capture system in human patients, exosomes from plasma were first isolated and shown to be round-shaped ( Fig. 2A , TEM picture on left) with average diameter of 80 nm ( Fig.  2A , summary of histogram on right). Particular exosomal marker proteins, CD63 and TSG101, were further used to confirm the identity of the isolated vesicles (Fig. 2B) . Furthermore, DLS were applied to total exosomes isolated from plasma samples to verify the size of exosomes and their size distribution. A typical distribution of the hydrodynamic radius of the exosomes obtained from DLS measurements is shown in Fig. 2C . Magnetic beads conjugated with antiEpCAM and anti-PSMA antibodies were then investigated to determine whether they were capable of capturing tumor-derived exosomes from plasma. For this purpose, total exosomes were isolated from the plasma (400 μl) of healthy controls and PCa patients by a commercial kit, and these total exosomes were then incubated with EpCAM and PSMA magnetic beads to further enrich tumor-derived exosomes. As shown in Fig. 2D, C1 and C2 are healthy individuals, and P1 to P5 are PCa patients. PCa patients exhibited higher expression of CD63 in isolated exosomes than the healthy controls, suggesting that magnetic beads conjugated with anti-EpCAM and anti-PSMA antibodies have higher affinity for exosomes derived from PCa patients' plasma. To further test the specificity of our dual-antibody immunoaffinity system, Western blot analysis for tumor-derived exosomes from patients and healthy controls. Almost no exosomes were captured by EpCAM and PSMA beads from the healthy controls. (E) RT-qPCR data on two lncRNA expression levels for total exosomes and tumor-derived exosomes from patients with PCa, patients with BPH and healthy individuals. The contents of the two lncRNAs in tumor-derived exosomes is higher than that in total exosomes. . 3 . SAP30L-AS1 and SChLAP1 expression in prostate tumorderived exosomes among subgroups. The relative expression was determined using RT-qPCR. (A) SAP30L-AS1 levels in the BPH group were higher than those in the healthy control group. (B) SChLAP1 expression was significantly higher in the PCa group than in the BPH group and the healthy control group. Cell
three patients with BPH were included in our test, then real-time RT-PCR was employed to quantify expression of SChLAP1 and SAP30L-AS1 in total exosomes and immunecaptured exosomes. Consistent with our observation on exosomes derived from cancer cell lines, it was found that, firstly, these two lncRNAs were upregulated in total exosomes derived from PCa patients as compared to that in either normal individuals or patients with BPH; and, secondly, our dual-antibody immunoaffinity system further enriched two lncRNAs in tumor-derived exosomes from total exosomes from PCa plasma, although this was not the case for exosomes from either normal individuals or patients with BPH (Fig. 2E) . Taken together, our results suggest that our dualantibody immunoaffinity system can effectively enrich tumor-derived exosomes for further analysis.
The expression levels of SAP30L-AS1 and SChLAP1 in tumor-derived exosomes
After the establishment of our capture approach, experiments were performed with a larger cohort of plasma samples to compare the exosomal SChLAP1 and SAP30L-AS1 levels among PCa patients, BPH patients and healthy volunteers by RT-qPCR. The RNA was extracted from tumor-derived exosomes of PCa patients and total exosomes of patients with BPH and healthy volunteers. It was found that the SAP30L-AS1 level in BPH patients was significantly higher than that in controls and PCa patients (controls vs. BPH, P<0.0001; BPH vs. PCa, P<0.05; Fig. 3A) . Interestingly, expression of SChLAP1 was significantly downregulated in BPH patients when compared to the level in controls and PCa patients (P<0.0001; Fig. 3B ). Meanwhile, the SChLAP1 level in PCa patients was significantly upregulated compared to the level in healthy individuals (P<0.0001; Fig. 3B ). Thus, our results suggest that it might be useful to quantify exosomal lncRNA levels to diagnose BPH and PCa.
The association of expression of lncRNAs in tumor-derived exosomes with patients' clinicopathological parameters
To further test the clinical application of the level of lncRNAs in tumor-derived exosomes, the relationship between exosomal lncRNAs and clinicopathological parameters Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry in PCa patients was analyzed. As shown in Table 1 , there was no relationship between the expression of these lncRNAs levels of PCa patients and clinicopathological features including age, lymphatic metastasis and development of metastasis. However, SAP30L-AS1 level was found to be related to PSA values and tumor invasion ( Fig. 4A and B) . Furthermore, SChLAP1 expression was significantly higher in PCa patients with higher Gleason scores (Fig. 4C) .
Utility of tumor-derived exosomal SAP30L-AS1 and SChLAP1 diagnostic prediction for PCa
We constructed ROC curves to estimate the diagnostic value of exosomal SAP30L-AS1 and SChLAP1, so as to assess their potential for clinical application. The integration of the area under the ROC curve indicated that SAP30L-AS1 and SChLAP1 had adequate diagnostic value for differentiating PCa patients from the controls (Fig. 5, A and B) . The area of the combination of two lncRNAs was equal to 0.92, but the sensitivity was not as good as for SChLAP1 solely (Fig. 5C and Table 2 ). In order to further investigate the potential value of exosomal lncRNAs as clinical biomarkers for diagnosing PCa, two lncRNAs separately combined with PSA were possessed of a moderate ability for discriminating between PCa patients and controls (Fig. 5, D and E) . However, the diagnostic value of two lncRNAs combined with PSA was not obvious (Fig. 5F and Table 2 ). Meanwhile, exosomal SAP30L-AS1 and SChLAP1 were also found to have significant diagnostic value for BPH (see online suppl. material, Fig. S2 and Table 2 ). 
Tumor-derived exosomal SChLAP1 detects PCa in patients with PSA levels of 4-10 ng/ml
When the concentration of PSA was 4-10ng/ml which was defined as the gray zone, the PSA test had low specificity. In present research, SAP30L-AS1 and SChLAP1 were investigated to determine whether they could be effective in differentiating between BPH and PCa in the PSA gray zone (Fig. 6, A and B) . Interestingly, the expression of tumor-derived exosomal SChLAP1 in PCa was higher than that in total exosomes from patients with BPH (Fig. 6B) . Therefore, exosomal SChLAP1 was promising in terms of helping doctors to make the diagnosis as to whether a patient with a PSA level in the gray zone had PCa, which could help to reduce unnecessary biopsies. To further evaluate the ability of exosomal SChLAP1 expression in plasma to discriminate between BPH and PCa in patients with a PSA level of 4-10 ng/ml, the ROC curves were plotted in Fig. 6C . The area under the ROC curve is 0.9898.
Discussion
Researchers have found that circulating exosomes in plasma contain a group of proteomic and genetic signatures in various diseases, especially cancer, thus presenting an enormous opportunity in terms of cancer diagnosis [38] . However, this is technically challenging due to the lack of an effective method for enriching tumor-derived exosomes from total exosomes. Therefore, obtaining high purity exosomes is necessary before further exploration of their functional mechanism and composition. A plethora of purification approaches for exosome isolation have been reported, including ultracentrifugation, filtration, chemical precipitation, affinity-binding beads and microfluidics techniques [39, 40] . Sequential centrifugation followed by ultracentrifugation is the most common approach used to isolate total exosomes [41] . However, this method is time consuming and demanding in terms of instrumentation [39] . Immunocapture using tumor-specific proteins on exosome surface antibodies (e.g., anti-HER2/neu or PSMA) is another optimized method which has emerged as a viable choice for exosome purification [38, 42] .
In the present study, a immunocapture method was developed using magnetic beads conjugated with anti-EpCAM and anti-PSMA antibodies to isolate prostate tumor-derived exosomes from plasma (Fig. 7 ). An exosome precipitation reagent was used, followed by immunoaffinity isolation to purify prostate tumor-derived exosomes, a process which is relatively quick and easy. Furthermore, tumor-derived exosomes might reflect both the individual characteristics of patients and adequate representative messages to diagnose prostate tumor [43] . In the current study, tumor-derived exosomes were characterized in cell culture medium and in clinical samples from PCa patients. Our results show that the dual-antibody capture system can effectively capture tumor-derived exosomes from total exosomes. EpCAM and PSMA are marker proteins that are frequently overexpressed in PCa exosomes [30, 44] . EpCAM is a ubiquitous cancer marker expressed exclusively in epithelial cells and epithelium-originated tumors, and it has been used as a specific antibody to isolate tumor-derived exosomes to avoid the interference of exosomes from nonepithelial tissues [44, 45] . PSMA is generally regarded as a biomarker enriched in exosomes from PCa cells, and its levels were significantly increased in plasma-derived exosomes from PCa patients compared with healthy individuals [30, 40] . Recent studies suggest that the expression level of PSMA is even higher than EpCAM in exosomes from PCa cell lines [40] . Thus, the dualantibody capture system is superior to the single EpCAM system. In our study, it was found that conjugation of anti-EpCAM and anti-PSMA antibodies to magnetic beads was effective for enriching exosomes specifically from PCa patients as compared to healthy individuals. More importantly, further studies were designed to test whether lncRNAs in purified tumorderived exosomes could serve as potential biomarkers for PCa diagnosis. Liquid biopsy is a blood test that encompasses the analysis of circulating tumor cells, circulating tumor DNA and exosomes derived from cancer cells [46, 47] . So far, every cell that has been studied secretes exosomes. Previous studies have demonstrated that tumor-derived exosomes had higher content of miRNA and lncRNA [18, 32, 48, 49] . It was the first of these studies that indicated that exosomes could transport mRNA, miRNA and angiogenic proteins leading to tumor growth and providing blood-based diagnostic information [47] . More recent researches efforts have demonstrated that tumor-derived exosomes have potential for use as noninvasive diagnostic biomarkers, as opposed to traditional tissue biopsy [24, 32, 40, 48] . The detection of tumor-derived exosomal lncRNAs has some obvious advantages. First, the collection of peripheral blood to obtain exosomes is easily available and minimally invasive. Second, blood samples could be taken at any time during treatment to achieve realtime and dynamic monitoring of molecular changes in disease and in tumors. Finally, the After establishing the capture system of prostate tumor-derived exosomes, a diagnostic analysis of tumor-derived exosomal lncRNAs was constructed. LncRNA SChLAP1 is an emerging molecule which is an important mediator for tumor invasion and hematogenous metastasis. SChLAP1 levels can independently predict tumor metastasis and PCa specific mortality [11] . In our study, SChLAP1 could effectively discriminate PCa patients from individuals with BPH, as well as healthy controls. The Gleason score is one of the most commonly used pathological parameters to assess the aggressiveness of PCa. SChLAP1 was significantly higher in PCa patients with higher Gleason scores, consistent with previous studies [50] . However, the Gleason score for prostate biopsy sometimes differs from the Gleason score after radical prostatectomy [51] . The present results also indicate that expression of SChLAP1 correlates with Gleason score. SChLAP1 may therefore be a favorable biomarker for assessing various treatment options for patients with PCa. Another lncRNA, SAP30L-AS1, was one of the lncRNAs existing in exosomes isolated from four PCa cell lines [18] . The current study is the first study to investigate the expression of SAP30L-AS1. The SAP30L-AS1 level in BPH patients was significantly higher than that in controls and PCa patients. In addition, SAP30L-AS1 level was positively correlated with PSA levels and tumor invasion in our clinical analysis. However, the exact mechanism requires further research.
As is well known, the PSA test is the most common method for PCa screening. Nevertheless, the PSA test has a limitation in that the specificity decreases drastically when PSA levels are in the gray zone [5] . Therefore, there is an unmet medical need to find a non-invasive diagnostic biomarker which can distinguish the low-and high-risk patients for clinical decision making. As an emerging technology, the SERS diagnostic approach has shown great potential for differentiating between PCa and BPH patients who had a PSA level in the gray zone, through analyzing the biochemical constituents in serum [52] . However, the technology is unwieldy and inappropriate for most clinical settings. Exosomal lncRNA-p21 levels were also proven to distinguish PCa from BPH [34] . In our study, the expression of tumor-derived exosomal SChLAP1 in PCa was higher than that in total exosomes from BPH patients. Exosomal SChLAP1 showed promise for helping doctors to make the diagnosis, and it could potentially reduce unnecessary biopsies. Also, the diagnostic performance of SChLAP1 in tumor-derived exosomes is perfect, with an area under the ROC curve of 0.9898. The integration of the area under the ROC curve indicated that both SAP30L-AS1 and SChLAP1 had adequate diagnostic value for PCa and BPH. Further analysis showed that the combination of two lncRNAs and PSA achieved a better diagnostic accuracy. Thus, SChLAP1 and SAP30L-AS1 may represent a promising target for PCa diagnosis.
It is worth noting that our study was limited by small clinical samples. As a future direction, different groups of patients with therapies and CRPC will be compared in order to study the correlation of EpCAM/PSMA levels with the progression of cancer.
In conclusion, our study demonstrates for the first time that the detection of tumorderived exosomal lncRNAs in plasma may lead to the identification of biomarkers with potential diagnostic applications in PCa. SAP30L-AS1 and SChLAP1 are promising markers which show with potential for the detection and stratification of PCa. Further analysis is still essential to test the exact molecular mechanisms of SAP30L-AS1 and SChLAP1 in the regulation of PCa.
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